

**Probiotic-Derived Factors for the Treatment and Prevention
of 5-Fluorouracil-Induced Intestinal Mucositis**

Luca David Prisciandaro

School of Animal and Veterinary Sciences

The University of Adelaide

October 2012

Contents

Declaration.....ix

Acknowledgements.....x

Dedication xiii

Publications derived from thesis.....xiv

Conference proceedings derived from this thesis.....xv

Abstract.....xvii

Abbreviationsxx

Chapter 1. Evidence supporting the use of probiotics for the prevention and treatment of chemotherapy-induced intestinal mucositis1

 1.1 Intestinal mucositis..... 2

 1.2 Probiotics..... 4

 1.3 Rationale for use of probiotic-based therapies 5

 1.3.1 Anti-inflammatory effects..... 6

 1.3.2 Maintenance of intestinal permeability..... 8

 1.3.3 Elimination of pathogenic bacteria 11

 1.3.4 Prevention of cell apoptosis 12

 1.3.5 Maintenance of the intestinal and mucus barrier 15

1.3.6	Prevention of oxidative damage.....	17
1.4	Risks associated with the use of probiotic based therapies	18
1.5	Probiotics in intestinal mucositis.....	19
1.5.1	Animal models of intestinal mucositis.....	19
1.5.2	Clinical trials	21
1.6	Summary	22
1.7	Table	25
Chapter 2. Probiotic factors partially protect intestinal cells from chemotherapy-induced cytotoxicity and improve parameters of 5-fluorouracil-induced intestinal mucositis in rats.....		27
2.1	Introduction	28
2.2	Materials and methods.....	30
2.2.1	Supernatant preparation	30
2.2.1	Cell culture.....	30
2.2.2	Effect of supernatants on cell viability	31
2.2.3	Assessment of protective effects of supernatants against 5-fluorouracil-induced damage	32
2.2.4	Animal trial protocol.....	32

2.2.5 Histological analysis	33
2.2.6 Myeloperoxidase activity.....	34
2.2.7 Sucrase activity	34
2.2.8 Mucin staining	35
2.2.9 Statistical analysis.....	35
2.3 Results	36
2.3.1 Effects of supernatant preparations on cell viability and number	36
2.3.2 Effect of 5-fluorouracil on IEC-6 cell viability and number and the protective effects of supernatant preparations.	36
2.3.3 Metabolism parameters and organ data	36
2.3.4 Myeloperoxidase activity.....	37
2.3.5 Sucrase activity	37
2.3.6 Histological severity scoring and analysis.....	38
2.3.7 Mucin staining	38
2.4 Discussion	39
2.5 Figure Legends and Figures	48
2.6 Tables	53

Chapter 3. Probiotic factors partially prevent 5-fluorouracil-induced changes to caspase 3 and 7 activation and transepithelial electrical resistance *in vitro*.59

3.1 Introduction	60
3.2 Materials and methods.....	61
3.2.1 Supernatant preparation	61
3.2.2 Transepithelial electrical resistance	61
3.2.3 Caspase 3/7 activity.....	62
3.2.4 Statistical analysis	63
3.3 Results	64
3.3.1 Transepithelial electrical resistance	64
3.3.2 Caspase 3/7 activity.....	64
3.4 Discussion	65
3.5 Figure legends and figures	70

Chapter 4. Effects of probiotic factors pre-treatment on 5-fluorouracil-induced intestinal mucositis in rats.73

4.1 Introduction	74
4.2 Materials and methods.....	77
4.2.1 Live bacteria and supernatant preparation	77

4.2.2 Animal trial protocol.....	77
4.2.3 Histological analysis and mucin staining.....	78
4.2.4 Myeloperoxidase and sucrase activity	78
4.2.5 Proliferating cell nuclear antigen staining	79
4.2.6 Detection of apoptotic cells	79
4.2.7 Statistical analysis.....	80
4.3 Results	81
4.3.1 Metabolism parameters and organ data	81
4.3.2 Histological analysis and mucin staining.....	82
4.3.3 Myeloperoxidase activity.....	82
4.3.4 Sucrase activity.....	82
4.3.5 PCNA and apoptosis staining	83
4.4 Discussion	83
4.5 Figure legends and figures	90
4.6 Tables	97
Chapter 5. Effects of proteinase or acid-treatment on probiotic factors.....	100
5.1 Introduction	101

5.2 Materials and methods.....	102
5.2.1 Supernatant preparation	102
5.2.2 Acid and proteinase treatment of supernatants	103
5.2.3 Cell density and 5-fluorouracil dose determination.....	103
5.2.4 WST-1 cell cytotoxicity assay	104
5.2.5 Statistical analysis.....	105
5.3 Results	105
5.3.1 Cell density and 5-fluorouracil dose determination pilot study.....	105
5.3.2 Effect of <i>E. coli</i> Nissle 1917 supernatants on cell proliferation	106
5.3.3 Effect of <i>L. rhamnosus</i> GG supernatants on cell proliferation.....	106
5.4 Discussion	106
5.5 Figure legends and figures	111
Chapter 6. Summary and conclusions.....	115
6.1 Introduction	116
6.2 Probiotic factors partially protect intestinal cells from chemotherapy-induced cytotoxicity and improve parameters of 5-fluorouracil-induced intestinal mucositis in rats	118

6.3 Probiotic factors partially prevent changes to caspases 3 and 7 activation and transepithelial electrical resistance in a model of 5-fluorouracil-induced epithelial cell damage..... 119

6.4 Effects of pre-treatment with probiotic factors on 5-fluorouracil-induced intestinal mucositis in rats 120

6.5 Exposure to proteases and acidic conditions can reduce efficacy of probiotic SNs in the prevention of 5-fluorouracil-induced damage to epithelial cells: a pilot study121

6.6 Overall conclusions 122

7. References128

8. Appendices.....159

Declaration

This thesis contains no material that has been accepted for the award of any other degree or diploma in any University or other tertiary institution and to the best of my knowledge and belief contains no material previously published or written by another person except where due reference has been made in the text.

I give consent for this copy of my thesis, when deposited in the University Library, being available for loan and photocopying.

Date

Luca Prisciandaro

Acknowledgements

This thesis would not have been completed without the support of the following people. Each of them played a major role and a part of this work belongs to them. I will be forever grateful to you all.

I would like to express my sincerest gratitude to my supervisors. To Professor Gordon Howarth who was always prepared to provide a sounding board for ideas and who allowed me to work independently and without restriction. Thank you for providing me with many opportunities that I probably wouldn't have pursued if not for your subtle persistence. To Dr Mark Geier, thank you for all your help during my animal trials and the preparation of my thesis, for being the first port of call for any issues which arose, and I apologise profusely for all the terrible first drafts I asked you to read!

I would also like to thank all of the people who directly contributed to the completion of this project. To Kerry Lymn, for her tireless efforts during my animal trials, and her constant willingness to help in whatever way possible. To Dr Roger Yazbek, my 'unofficial' supervisor, thank you for showing me everything a successful PhD student and researcher should be. To Jane Fauser who taught me everything I know about cell culture work and providing a support during difficult times. To Ms Ann Chua, for teaching me how to use a voltmeter and assisting with cell culture work. To Professor Ross Butler and Associate Professor Adrian Cummins for welcoming me into their laboratories so that I could complete experiments.

To my wonderful colleagues at Roseworthy Campus who I am now proud to call my friends. A special mention must go to Ruth Lindsay and Kate Plush, thank you for brightening up even the darkest days, for listening to my endless chatter about everything but my PhD, for our morning tea breaks, our extended lunch breaks and the barely memorable nights out. You both made the last four years a much more enjoyable experience. I would also like to thank Kylie Chenoweth, Nicole Heberle, Rebecca Forder, Dr Bob Hughes (the crossword king), Professor Phil Hynd, Robyn Terry, Sarah Truran, Michael Wilkes, Natasha Penno and Kath Brice; you all helped me in different, irreplaceable ways and I wish you all the best.

I would not have survived without a strong support network outside of work. To my family: Dad, Mum, Daniela, Gloria and Con, thank you for your support and interest even if what I was talking about made no sense. To Chanelle Corena, my partner throughout this time, you provided me with a constant source of inspiration and motivation. I will be forever grateful for your support, encouragement and patience. To my closest friends: James Kitschke, Scott Grimes, Adrian Porcaro, Robert Valente, Christian Martino, Levi McCusker and Bartek Skrodzki - thank you for the hilarious email chains, the weekly indoor soccer and all the fantastic memories we created each and every weekend. It was great to know that no matter how frustrating my project became, there would always be someone willing to help me forget come Saturday night!

Last but not least, to my best friend and the most handsome dog in the world, Rocky.
Thank you for showing me that even if I've just wasted months on an experiment that didn't work, a simple game of fetch can make me feel better.

Dedication

I would like to dedicate this thesis to my mother Rita who passed away during the first year of my project. Throughout her life she never hesitated to put our needs before her own, and did whatever was necessary to help her children. Her confidence and spirit during her illness was an inspiration to me. She was a role model in every sense of the word and peaked my interest in education and learning at a young age. I am the person that I am today largely because of her.

Publications derived from thesis

PRISCIANDARO, L. D., GEIER, M. S., CUMMINS, A.G., BUTLER, R.N., HOWARTH, G.S. 2009. Probiotics and their derivatives as a treatment for inflammatory bowel disease? *Inflammatory Bowel Diseases*, 15(12):1906-14.

PRISCIANDARO, L. D., GEIER, M. S., CUMMINS, A.G., BUTLER, R.N., HOWARTH, G.S. 2011. Evidence supporting the use of probiotics for the prevention and treatment of chemotherapy-induced mucositis. *Critical Reviews in Food Science and Nutrition*, 51(3):239-47

PRISCIANDARO, L. D., GEIER, M. S., CUMMINS, A.G., BUTLER, R.N., HOWARTH, G.S. 2011. Probiotic factors partially improve parameters of 5-Fluorouracil induced intestinal mucositis in rats. *Cancer Biology and Therapy*, 11(7):671-77.

PRISCIANDARO, L.D., GEIER, M.S., CHUA, A.E., CUMMINS, A.G., BUTLER, R.N., SANDER, G.R., HOWARTH, G.S. 2012. Probiotic factors partially prevent changes to caspases 3 and 7 activation and transepithelial electrical resistance in a model of 5-fluorouracil-induced epithelial cell damage. *Supportive Care in Cancer* [Article in press].

Conference proceedings derived from this thesis

PRISCIANDARO, L. D., GEIER, M. S., CUMMINS, A.G., BUTLER, R.N., HOWARTH, G.S. 2010. Pre-treatment with probiotic factors protect intestinal cells from 5-fluorouracil-induced changes to transepithelial resistance and caspase 3/7 activation. *Australian Gastroenterology Week*. Gold Coast, Australia.

PRISCIANDARO, L. D., GEIER, M. S., CUMMINS, A.G., BUTLER, R.N., HOWARTH, G.S. 2010. Pre-treatment with probiotic factors protect intestinal cells from 5-fluorouracil-induced changes to transepithelial resistance and caspase 3/7 activation. *Australian Society for Medical Research State Meeting*. Adelaide, Australia.

PRISCIANDARO, L. D., GEIER, M. S., CUMMINS, A.G., BUTLER, R.N., HOWARTH, G.S. 2009. Probiotic factors protect intestinal cells from chemotherapy-induced cytotoxicity and improve parameters of 5-fluorouracil induced intestinal mucositis in rats. *Australian Gastroenterology Week*. Sydney, Australia.

PRISCIANDARO, L. D., GEIER, M. S., CUMMINS, A.G., BUTLER, R.N., HOWARTH, G.S. 2009. Compounds secreted from *Escherichia coli* Nissle 1917, *Streptococcus thermophilus* TH-4 and *Lactobacillus fermentum* BR11 maintain intestinal cell viability following 5-FU administration *In vitro*. *Multinational Association for Supportive Care in Cancer Symposium*. Rome, Italy.

PRISCIANDARO, L. D., GEIER, M. S., CUMMINS, A.G., BUTLER, R.N., HOWARTH, G.S. 2009. Factors secreted from *Lactobacillus fermentum* BR11 and *Escherichia coli* Nissle 1917 as a potential therapy for 5-fluorouracil induced mucositis: A pilot study. *Multinational Association for Supportive Care in Cancer Symposium*. Rome, Italy.

PRISCIANDARO, L. D., GEIER, M. S., CUMMINS, A.G., BUTLER, R.N., HOWARTH, G.S. 2008. Soluble products secreted from the newly identified probiotic *Lactobacillus fermentum* BR11 improves viability of rat intestinal cells. *Nutrition Society of Australia Annual Meeting*. Adelaide, Australia.

Abstract

5-fluorouracil (5-FU) is one of the most commonly prescribed anti-neoplastic drugs in modern cancer treatment. Although the drug is effective at destroying cancer cells, its administration is accompanied by serious, dose-limiting side effects, amongst the most prevalent of which is intestinal mucositis. This disorder is characterised by ulceration and inflammation of the small intestine, and sufferers often experience severe abdominal pain, nausea and diarrhoea. Despite its predominance, there are currently no definitive treatments for intestinal mucositis.

Probiotics are defined as live bacteria which are able to exert beneficial physiological or therapeutic effects. Strains can be sourced from either food or the human microbiota, but must meet specific requirements prior to being officially recognised as probiotics. The mechanisms of probiotic action are highly species and strain specific, however, a number of strains have been shown to exert beneficial effects which may be suited to the treatment of intestinal mucositis. These include; inhibition of pathogenic bacterial growth and inflammation, maintenance of cell cycling and strengthening of the intestinal barrier. While the majority of probiotic research has focused on the use of live bacteria, there has been a recent interest in bioactive factors that are secreted by the bacterial cells into the cell-free supernatant (SN). There are a range of benefits to using SNs in preference to live bacteria, such as reduced risk of sepsis and greater quality control during production. This thesis represents the first detailed examination into the efficacy of probiotic-based SNs in the treatment of 5-FU-induced intestinal mucositis.

Firstly, four different probiotic SNs were investigated *in vitro* for their ability to maintain cell growth following administration of 5-FU. The two strains deemed most effective were then assessed in an *in vivo* model of intestinal mucositis. Rats were treated with SNs both before and after 5-FU administration. Improvement was reported in some indicators of intestinal damage in rats following SN administration. However, the overall effects were less pronounced than expected, given the extent of improvement reported in the *in vitro* model. These findings suggested that a different screening method was required prior to *in vivo* examination, and that the current *in vivo* treatment protocol required review.

As mucositis occurs only following chemotherapy administration, there is opportunity to administer therapeutic compounds prior to the onset of the disorder with the aim of preventing its development, rather than treating the damage. Two strains, *Lactobacillus rhamnosus* GG (LGG) and *Escherichia coli* Nissle 1917 (EcN), were examined for their ability to prevent 5-FU-induced reduction in intestinal barrier function and increased epithelial cell apoptosis in an *in vitro* model. Both SNs inhibited 5-FU-induced changes to barrier function and apoptosis. The success of these strains in a preventative treatment regime warranted further investigation *in vivo*. However, in the rat model of 5-FU-induced mucositis, no significant protective effects were observed. These findings highlighted inconsistencies between *in vitro* and *in vivo* models. One reason for this disagreement may have been due to the degradation of active compounds during gut transit. In order to determine if acidic or proteinase-rich conditions (two characteristics of the gastric environment) altered the efficacy of LGG and EcN SNs, a small *in vitro* pilot study was performed. All SNs not exposed to either acidic

or proteinase-rich conditions were effective in maintaining cell proliferation following 5-FU administration, but the efficacy of LGG SN was significantly reduced following protease- and acid-treatment. However, neither treatment diminished the efficacy of EcN SN. These results suggested a requirement for new administration techniques to allow the SNs to reach their target area.

In summary, this thesis explores the potential use of probiotic-derived factors to treat 5-FU-induced intestinal mucositis. It describes the capacity for LGG and EcN SNs to improve parameters of chemotherapy-induced damage *in vitro*. These strains were less effective *in vivo*, however, further investigations into effective delivery methods are warranted to ensure that the active compounds reach the small intestine. This thesis provides support for future investigations into the use of probiotic SNs for the treatment of intestinal mucositis.

Abbreviations

5-FU	5-fluorouracil
ANOVA	Analysis of variance
BR11	<i>Lactobacillus fermentum</i> BR11
CEC	CytoScan electron carrier
CM	Culture media
DMEM	Dulbecco's modified eagle medium
DPBS	Dulbecco's phosphate buffered saline
DSS	Dextran Sulphate Sodium
EcN	<i>Escherichia coli</i> Nissle 1917
EGCG	Epigallocatechin gallate
EGF	Epidermal growth factor
GLP-2	Glucagon-like peptide-2
HID-AB	High iron diamine-alcian blue
IFN	Interferon
IL	Interleukin
JI	Jejunum-ileum junction
LGG	<i>Lactobacillus rhamnosus</i> GG
LPS	Lipopolysaccharide
MCP	Monocyte chemotactic protein
MPO	Myeloperoxidase
MRS	de Man rogosa and sharpe
MTX	Methotrexate

NF-κB	Nuclear factor-κB
PAS	Periodic acid-schiff
ROS	Reactive oxygen species
SN	Supernatant
TEER	Transepithelial electrical resistance
TH-4	<i>Streptococcus thermophilus</i> TH-4
TNBS	Trinitrobenzene sulphonic acid
TNF	Tumour necrosis factor
TSB	Tryptic soy broth
ZO	Zonula occluden